faldaprevir Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.   Wikipedia

Chemistry

  • SMILES: COc1ccc2c(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](NC(=O)OC4CCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)O)cc(nc2c1Br)c6csc(NC(=O)C(C)C)n6
  • InChIKey: LLGDPTDZOVKFDU-XUHJSTDZSA-N
  • Mol. Mass: 869.84
  • ALogP: 6.3
  • ChEMBL Molecule:
    faldaprevir  
More Chemistry

Pharmacology

Alternative names

bi201335 | bi 201335 | bi-201335 | faldaprevir | faldeprevir | n-((cyclopentyloxy)carbonyl)-3-methylvalyl-4-((8-bromo-7-methoxy-2-(2-((2-methylpropanoyl)amino)-1,3-thiazol-4-yl)quinolin-4-yl)oxy)-n-(1-carboxy-2-ethenylcyclopropyl)prolinamide

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Healthy Volunteers (Phase 1)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

HIV Infections (Phase 1)

Liver Cirrhosis (Phase 1)

Pharmacokinetics (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 49
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue